English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

bridge to durable LV assist device (LVAD). The Impella 5.0 was inserted for refractory cardiogenic shock in a 50-year-old man with acute deterioration of end-stage dilated cardiomyopathy and systolic blood pressure 78 mmHg despite the presence of inotropes (Figure), because the Impella 2.5 or intra-aortic balloon pumping could not provide sufficient circulatory support. Circulatory support by the P6 assist level of the Impella 5.0, which produces a 3.7-L/min pump flow, immediately S hort-term mechanical circulatory support has been used to improve the hemodynamics in refractory cardiogenic shock. The Impella 5.0 (Abiomed), a microaxial blood pump, is a minimally invasive heart assist device that can be used to stabilize cardiogenic shock patients by delivering an up to 5-L/min blood flow to the aorta while directly unloading the left ventricle (LV). We describe the first clinical application of the Impella 5.0 for cardiogenic shock in Japan, in which it was used as a

Impella 5.0 as a Bridge to Implantable Left Ventricular Assist Device ― First Clinical Case in Japan ―